Nicholas Hoffman & Company LLC. Has $1.44 Million Stock Position in Sanofi (NASDAQ:SNY)

Nicholas Hoffman & Company LLC. lowered its holdings in shares of Sanofi (NASDAQ:SNY) by 2.7% in the third quarter, HoldingsChannel reports. The firm owned 25,014 shares of the company’s stock after selling 682 shares during the period. Nicholas Hoffman & Company LLC.’s holdings in Sanofi were worth $1,442,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Boston Partners lifted its stake in shares of Sanofi by 0.3% during the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock worth $635,280,000 after buying an additional 33,657 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after acquiring an additional 1,370,232 shares during the period. Barrow Hanley Mewhinney & Strauss LLC grew its position in shares of Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares during the last quarter. Mondrian Investment Partners LTD increased its stake in shares of Sanofi by 43.1% during the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock worth $192,023,000 after purchasing an additional 1,190,141 shares during the period. Finally, Envestnet Asset Management Inc. lifted its holdings in Sanofi by 8.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after purchasing an additional 246,224 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SNY. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Argus raised their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $53.83 on Wednesday. The firm has a 50 day moving average of $56.06 and a 200-day moving average of $51.89. Sanofi has a 12 month low of $44.05 and a 12 month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $136.61 billion, a PE ratio of 27.46, a PEG ratio of 1.55 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 20.59%. The business had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same period in the previous year, the business earned $2.55 earnings per share. The company’s revenue was up 12.3% on a year-over-year basis. On average, equities research analysts predict that Sanofi will post 4.25 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.